DelveInsight's 'Primary Myelofibrosis Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline primary myelofibrosis therapies in various stages of ...
Please provide your email address to receive an email when new articles are posted on . Study results presented at Society of Hematologic Oncology Annual Meeting highlight the potential effect that ...
Review of criteria used to assess and plan treatment for a 67-year-old patient with primary myelofibrosis. John Mascarenhas, MD: Let’s move on to the first patient case. This is a 67-year-old woman ...
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Primary Myelofibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...
Moshe Talpaz, MD: Let’s discuss a little bit of myelofibrosis. Myelofibrosis is a relatively uncommon disease that is part of a group of conditions known as myeloproliferative neoplasia. Those are ...
A group of investigators from Mayo Clinic and multiple academic research centers in Italy have identified a genetic model for predicting outcomes in patients with primary myelofibrosis who are 70 ...
Moving on to review the first patient scenario of primary myelofibrosis, panelists elucidate the decisionmaking process when selecting JAK inhibitor therapy. This patient highlights one of the ...
The findings, coming from nearly a decade’s worth of retrospective data on patients aged at least 65 years, offer real-world evidence on the treatment’s impact on survival. Ruxolitinib (Rx) treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results